ProCE Banner Activity

Frequently Asked Questions on the Management of NAFLD/NASH

Clinical Thought
Here’s my take on bariatric surgery, noninvasive testing, and endpoints in patients with NASH.

Released: January 16, 2020

Expiration: January 14, 2021

No longer available for credit.

Share

Faculty

Manal F. Abdelmalek

Manal F. Abdelmalek, MD, MPH

Professor of Medicine
Division of Gastroenterology and Hepatology
Duke University
Durham, North Carolina

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Manal F. Abdelmalek, MD, MPH

Professor of Medicine
Division of Gastroenterology and Hepatology
Duke University
Durham, North Carolina

Manal F. Abdelmalek, MD, MPH, has disclosed that she has received consulting fees from Allergan, Bristol-Myers Squibb, Madrigal, NGM Pharma, Promethera, Prometic, Inventiva, and TaiwanJ; funds for research support from Allergan, Bristol-Myers Squibb, Boehringer-Ingelheim, Conatus, Galmed, Genfit, Gilead Sciences, Intercept, Inventiva, Poxel, Enyo, Durect, Progenity, Target-NASH, Madrigal, NGM Biopharma, Novartis, Novo Nordisk, Viking ; and fees for non-CME/CE services from Alexion and Intercept.